It was late April when the CDC added impaired taste and/or smell to its list of COVID-19 symptoms. Thanks to AI and natural language processing (NLP), researchers at the Medical University of South Carolina had beaten the federal agency to the punch.
Notching its fifth go-ahead from the FDA, an Israel-based AI startup has received the agency’s 510(k) clearance to market software that automatically identifies signs of compression fractures in the spine.
Researchers in South Korea have shown that AI trained on photos of both Asian and Caucasian patients can help dermatologists more accurately diagnose many diseases and disorders of the skin in both subpopulations.
The idea is to initially place the device in medical waiting areas, from where it would help prepare staff for caseload ebbs and flows. Later it might be set in larger public spaces, helping to monitor epidemiological trends at the population level.
Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus.